Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Elranatamab-bcmm + Inobrodib
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Elranatamab-bcmm Elrexfio PF-06863135|PF06863135|PF 06863135 CD3 Antibody 120 TNFRSF17 Antibody 22 Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov).
Inobrodib CCS-1477|CCS 1477|CCS1477 CBP/p300 inhibitor 13 Inobrodib (CCS-1477) binds to and inhibits p300 (EP300) and CBP (CREBBP) and inhibits NRF2-dependent transcription, potentially resulting in increased anti-tumor immune response, increased cell cycle arrest, and inhibition of tumor growth (PMID: 33431496, PMID: 39266679, PMID: 40127850, PMID: 39885312).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04068597 Phase Ib/II Azacitidine + Inobrodib Azacitidine + Inobrodib + Venetoclax Dexamethasone + Inobrodib + Pomalidomide Dexamethasone + Inobrodib + Ixazomib Inobrodib Elranatamab-bcmm + Inobrodib Inobrodib + Teclistamab Daratumumab + Inobrodib + Lenalidomide Inobrodib + Lenalidomide Bortezomib + Dexamethasone + Inobrodib Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies Recruiting USA | SWE | GBR | FRA | ESP 0


Additional content available in Icon for CKB-BoostCKB BOOST